Patterns of dyslipoproteinemia in selected North American populations. The Lipid Research Clinics Program Prevalence Study. 1986

J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison

This article describes the assignment of dyslipoproteinemia (DLP) in several free-living North American populations and presents mean lipid and lipoprotein levels for each type. Dyslipoproteinemic phenotypes were assigned by a modified version of the National Institutes of Health (Fredrickson) phenotyping system. Criteria for assigning phenotypes included age- and sex-specific 5th and 95th percentiles for low-density lipoprotein and high-density lipoprotein cholesterol and total triglyceride, as well as other qualitative and quantitative criteria. Phenotypes IIb, III, I, and V were uncommon, confirming clinical impressions of their frequency. Lipid and lipoprotein levels in specific phenotypes were generally as expected. In the type III phenotype, however, mean cholesterol and triglyceride levels were surprisingly low. Gonadal hormone use, in the form of both oral contraceptives and postmenopausal estrogens, was reported in approximately 30% of women in these populations and was associated with dramatic differences in the frequency of DLP when compared with women not taking hormones. In general, these differences reflected the previously described effects of estrogen and progestins on lipoprotein levels. These data gathered in free-living populations: confirm clinical impressions of the rarity of some phenotypes, focus attention on those phenotypes in which diminished rather than elevated lipoproteins are found, and provide further evidence of the effect of hormones on lipid and lipoprotein levels.

UI MeSH Term Description Entries
D006951 Hyperlipoproteinemias Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation. Hyperlipoproteinemia
D007009 Hypolipoproteinemias Conditions with abnormally low levels of LIPOPROTEINS in the blood. This may involve any of the lipoprotein subclasses, including ALPHA-LIPOPROTEINS (high-density lipoproteins); BETA-LIPOPROTEINS (low-density lipoproteins); and PREBETA-LIPOPROTEINS (very-low-density lipoproteins). Hypolipoproteinemia,Hypoprebetalipoproteinemia
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009656 North America The northern continent of the Western Hemisphere, extending northward from the Colombia-Panama border and including CENTRAL AMERICA, MEXICO, Caribbean area, the UNITED STATES, CANADA and GREENLAND. The term often refers more narrowly to MEXICO, continental UNITED STATES, AND CANADA. Northern America
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003276 Contraceptives, Oral Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both. Low-Dose Oral Contraceptive,Oral Contraceptive,Oral Contraceptives,Oral Contraceptives, Low-Dose,Oral Contraceptives, Phasic,Contraceptive, Low-Dose Oral,Contraceptive, Oral,Contraceptives, Low-Dose Oral,Contraceptives, Phasic Oral,Low Dose Oral Contraceptive,Low-Dose Oral Contraceptives,Oral Contraceptive, Low-Dose,Oral Contraceptives, Low Dose,Phasic Oral Contraceptives

Related Publications

J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
January 1986, Circulation,
J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
August 1979, Circulation,
J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
January 1986, Circulation,
J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
February 1980, Circulation,
J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
January 1986, Circulation,
J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
February 1985, The American journal of clinical nutrition,
J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
February 1985, The American journal of clinical nutrition,
J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
January 1986, Circulation,
J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
July 1982, Preventive medicine,
J C LaRosa, and L E Chambless, and M H Criqui, and I D Frantz, and C J Glueck, and G Heiss, and J A Morrison
November 1980, Circulation,
Copied contents to your clipboard!